Stocks
Zynerba Pharmaceuticals Financial Statements (ZYNE) |
||||||||||
| Zynerba Pharmaceuticalssmart-lab.ru | % | 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.03.2019 | 10.03.2020 | 10.03.2021 | 01.03.2022 | 28.03.2023 | 14.08.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.086 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| Operating Income, bln rub | -40.4 | -34.3 | -52.1 | -36.8 | -35.3 | -38.8 | ||||
| EBITDA, bln rub | ? | -39.9 | -34.2 | -52.5 | -36.2 | -34.6 | -38.3 | |||
| Net profit, bln rub | ? | -39.9 | -31.4 | -50.4 | -37.6 | -34.8 | -37.0 | |||
| OCF, bln rub | ? | -32.4 | -34.8 | -41.3 | -33.5 | -23.0 | -31.6 | |||
| CAPEX, bln rub | ? | 0.287 | 0.129 | 0.445 | 0.048 | 0.154 | 0.200 | |||
| FCF, bln rub | ? | -32.7 | -34.9 | -41.8 | -33.5 | -23.2 | -31.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 40.5 | 34.3 | 52.1 | 36.8 | 35.3 | 38.8 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, bln rub | 27.2 | 20.4 | 35.7 | 21.4 | 21.1 | 24.8 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.216 | 1.01 | ||||
| Assets, bln rub | 67.3 | 87.8 | 74.1 | 81.2 | 55.5 | 40.5 | ||||
| Net Assets, bln rub | ? | 57.6 | 75.6 | 60.1 | 70.9 | 46.2 | 29.0 | |||
| Debt, bln rub | 0.000 | 0.353 | 0.110 | 0.563 | 0.334 | 0.218 | ||||
| Cash, bln rub | 59.8 | 70.1 | 59.2 | 67.8 | 50.6 | 36.0 | ||||
| Net debt, bln rub | -59.8 | -69.7 | -59.0 | -67.2 | -50.3 | -35.7 | ||||
| Ordinary share price, rub | 2.97 | 6.04 | 3.30 | 2.88 | 0.530 | 1.21 | ||||
| Number of ordinary shares, mln | 15.3 | 22.0 | 27.0 | 39.3 | 42.7 | 50.2 | ||||
| Market cap, bln rub | 45 | 133 | 89 | 113 | 23 | 61 | ||||
| EV, bln rub | ? | -14 | 63 | 30 | 46 | -28 | 25 | |||
| Book value, bln rub | 58 | 76 | 60 | 71 | 46 | 29 | ||||
| EPS, rub | ? | -2.61 | -1.43 | -1.87 | -0.96 | -0.82 | -0.74 | |||
| FCF/share, rub | -2.13 | -1.59 | -1.55 | -0.85 | -0.54 | -0.63 | ||||
| BV/share, rub | 3.76 | 3.44 | 2.23 | 1.81 | 1.08 | 0.58 | ||||
| EBITDA margin, % | ? | -46 422% | ||||||||
| Net margin, % | ? | -46 408% | ||||||||
| FCF yield, % | ? | -71.9% | -26.3% | -46.8% | -29.6% | -102.5% | -52.5% | |||
| ROE, % | ? | -69.3% | -41.6% | -83.8% | -53.0% | -75.3% | -127.5% | |||
| ROA, % | ? | -59.3% | -35.8% | -68.1% | -46.3% | -62.7% | -91.4% | |||
| P/E | ? | -1.14 | -4.23 | -1.77 | -3.01 | -0.65 | -1.64 | |||
| P/FCF | -1.39 | -3.80 | -2.14 | -3.37 | -0.98 | -1.91 | ||||
| P/S | ? | 528.7 | ||||||||
| P/BV | ? | 0.79 | 1.76 | 1.48 | 1.59 | 0.49 | 2.09 | |||
| EV/EBITDA | ? | 0.36 | -1.85 | -0.57 | -1.27 | 0.80 | -0.65 | |||
| Debt/EBITDA | 1.50 | 2.04 | 1.12 | 1.86 | 1.45 | 0.93 | ||||
| R&D/CAPEX, % | 9 504% | 15 754% | 8 007% | 45 038% | 13 692% | 12 348% | ||||
| CAPEX/Revenue, % | 333.3% | |||||||||
| Zynerba Pharmaceuticals shareholders | ||||||||||
